Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Gains from Investment Securities: 2019-2024

Historic Gains from Investment Securities for Fulcrum Therapeutics (FULC) over the last 6 years, with Dec 2024 value amounting to $9.4 million.

  • Fulcrum Therapeutics' Gains from Investment Securities rose 10.46% to $11.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.9 million, marking a year-over-year increase of 10.46%. This contributed to the annual value of $9.4 million for FY2024, which is 6.19% down from last year.
  • Fulcrum Therapeutics' Gains from Investment Securities amounted to $9.4 million in FY2024, which was down 6.19% from $10.0 million recorded in FY2023.
  • Over the past 5 years, Fulcrum Therapeutics' Gains from Investment Securities peaked at $10.0 million during FY2023, and registered a low of $3.0 million during FY2020.
  • Its 3-year average for Gains from Investment Securities is $8.6 million, with a median of $9.4 million in 2024.
  • As far as peak fluctuations go, Fulcrum Therapeutics' Gains from Investment Securities skyrocketed by 75.14% in 2021, and later dropped by 6.19% in 2024.
  • Fulcrum Therapeutics' Gains from Investment Securities (Yearly) stood at $3.0 million in 2020, then spiked by 75.14% to $5.2 million in 2021, then increased by 25.36% to $6.5 million in 2022, then surged by 53.32% to $10.0 million in 2023, then fell by 6.19% to $9.4 million in 2024.